|
|
|
| NIH/NCI 2SC1GM127278-05A1 |
Contel (PI) |
06/01/18-05/31/2022 |
| Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugs |
|
$1,570,000 |
|
PSC-CUNY
Enhanced Research Award 2020 |
Contel, Hubbard (co-PIs) |
06/01/20-05/31/2021 |
Ruthenium-Based Small Molecules as Efficient,
Less Toxic, and Cost-Effective Chemotherapeutic Options Against Triple-Negative Breast Cancer |
$12,000 |
Completed Research Support
(Since joining Brooklyn College)
|
| NIH/NCI 1SC1CA182844-04 |
Contel (PI) |
07/01/13-06/30/2018 |
| Titanium-gold-based chemotherapeutics for prostate and kidney cancer |
$1,413,000 |
| Tow Foundation |
Contel (PI) |
06/01/15-05/31/2017 |
| Tow Professor 2015-2016 |
$25,000 (for research) |
|
Contel (PI) |
06/01/15-05/31/2016 |
| Improving selectivity and delivery of potential organometallic-based cancer chemotherapeutics by using peptide- and carbohydrate- amphiphiles as mobile nanocarriers |
$10,000 |
| NIH/NCI 1R13CA200223-01A1 |
Contel(PI) |
09/01/2015-05/31/2016 |
Organization Conferences:
1st International Symposium on Clinical and Experimental Metallodrugs in Medicine: Cancer Chemotherapy (CEMM).Honolulu (UHCC) December 2015 |
$5000 |
| NIH/NIGM SC2GM082307 |
Contel (PI) |
02/01/10-06/30/2013 |
| Organogold phosphorus-containing compounds as anticancer agents |
$471,000 |
| PSC-CUNY Research Award 2009 |
Contel (PI) |
07/01/09-06/30/2010 |
| Gold(III) compounds as anti-cancer agents |
$3,300 |
| PSC-CUNY Research Award 2008 |
Contel (PI) |
07/01/08-06/30/2009 |
| Gold compounds as greener oxidation homogeneous catalysts |
$3,500 |
| PSC-CUNY New Faculty Research Award 2007 |
Contel (PI) |
07/01/07-06/30/2009 |
| Gold compounds as environmentally benign catalysts for reactions with potential industrial applications |
$3,900 |